---

Urolithiasis: A Comprehensive Review

Based on Campbell-Walsh-Wein Urology (12th Ed.), Harrison's Principles of Internal Medicine (21st Ed.), Bailey & Love's Short Practice of Surgery (28th Ed.), and EAU/AUA Guidelines

---

1. INTRODUCTION & EPIDEMIOLOGY

• Lifetime prevalence: 10–15% in developed nations; rising globally
• Male:Female ratio: 2–3:1 (gap narrowing due to obesity epidemic)
• Peak incidence: 40–60 years of age
• Recurrence rate: ~50% within 5–7 years without preventive therapy; ~75% within 20 years
• "Stone Belt" (southeastern USA, Middle East, Indian subcontinent) — geographic clustering due to heat, dehydration
• Modern world witnessing steady increase in renal calculi coinciding with obesity, diabetes, and metabolic syndrome (Bailey & Love, p. 1495)

---

2. TYPES OF STONES & THEIR FREQUENCIES

"Many stones are a mixture of crystal types (e.g., calcium oxalate and calcium phosphate) and also contain protein in the stone matrix." (Harrison's, p. 8691)

---

3. PATHOPHYSIOLOGY & STONE FORMATION

3.1 Fundamental Principles (Campbell-Walsh-Wein)

Ion Activity Product (IAP) > Solubility Product (Ksp) → Crystallization

1. Nucleation — crystal nuclei form (homogeneous or heterogeneous)
2. Crystal growth — aggregation of crystals
3. Crystal retention — Randall's plaques (subepithelial calcium phosphate deposits at papillary tips) anchor crystals
4. Stone formation — organized mineral structure

3.2 Randall's Plaques

• Subepithelial apatite deposits in the renal papilla
• Serve as nidus for calcium oxalate monohydrate stone attachment
• Seen in idiopathic calcium oxalate stone formers (Campbell-Walsh-Wein)

3.3 Factors Promoting Crystallization

3.4 Inhibitors of Crystallization

• Citrate (most important — chelates calcium)
• Tamm-Horsfall protein (uromodulin)
• Osteopontin
• Nephrocalcin
• Magnesium

---

4. ETIOLOGY & RISK FACTORS

4.1 Metabolic Risk Factors

• Absorptive (Type I, II, III) — most common; excess intestinal Ca absorption
• Resorptive — hyperparathyroidism, bone resorption
• Renal — impaired tubular Ca reabsorption

• Primary hyperoxaluria (Types 1, 2, 3) — genetic enzyme defects; severe
• Enteric hyperoxaluria — Crohn's disease, bariatric surgery (Roux-en-Y), short bowel syndrome
• Dietary — excess spinach, nuts, chocolate, vitamin C megadoses

• Purine-rich diet, gout, tumor lysis syndrome
• Acts as heterogeneous nucleus for CaOx stones

• Distal RTA type I
• Chronic diarrheal states, IBD
• Hypokalemia
• High-protein diet

• Most significant modifiable risk factor
• Dehydration, hot climate, inadequate fluid intake

• Persistently acidic urine (pH <5.5) → uric acid stones
• Persistently alkaline urine (pH >6.5) → calcium phosphate, struvite

4.2 Systemic Conditions Associated with Stones

4.3 Dietary & Lifestyle Risk Factors

• High sodium intake → ↑ urinary calcium
• High animal protein → ↑ urinary uric acid, oxalate; ↓ citrate; ↓ urine pH
• Low calcium diet (paradoxically) → ↑ intestinal oxalate absorption
• Dehydration / low fluid intake
• Obesity (BMI >30)
• Sedentary lifestyle

4.4 Anatomical Risk Factors

• Ureteropelvic junction (UPJ) obstruction — urinary stasis
• Horseshoe kidney — impaired drainage
• Medullary sponge kidney
• Vesicoureteral reflux
• Urinary diversion (ileal conduit)
• Foreign bodies (stents, catheters as nidus)

---

5. CLINICAL PRESENTATION

5.1 Renal Colic (Classic Presentation)

• Onset: Abrupt, often waking patient from sleep
• Character: Colicky (waxes and wanes) — due to ureteral peristalsis against obstruction
• Severity: One of the most severe pains described; patients cannot find a comfortable position (unlike peritonitis where patients lie still)
• Radiation: Classically "loin to groin"; may radiate to genitalia
• Associated symptoms:
  • Nausea and vomiting (very common — due to shared celiac innervation)
  • Urinary urgency and frequency (distal ureteral stones)
  • Gross or microscopic hematuria (~85% cases)
  • Diaphoresis

5.2 Stone Location and Symptom Pattern

5.3 Physical Examination

• Costovertebral angle (CVA) tenderness — hallmark finding
• Patient is restless, writhing (distinguishes colic from peritonitis)
• Abdominal tenderness may be present
• Fever + CVA tenderness → infected obstructed stone — urological emergency

5.4 Special Situations

• Silent stones — large staghorn calculi may be asymptomatic; discovered incidentally
• Bilateral ureteral obstruction → anuria, acute kidney injury
• Obstructed infected kidney → urosepsis, pyonephrosis (emergency decompression required)

---

6. DIAGNOSIS

6.1 Laboratory Investigations

• Hematuria: Present in ~85% (microhematuria is common; absence does not exclude stone)
• Pyuria: Suggests concurrent UTI or struvite stone
• Urine pH: <5.5 (uric acid); >7.0 (struvite/infection)
• Crystals on microscopy:
  • Envelope-shaped (octahedral) → Calcium oxalate dihydrate
  • Dumbbell/biconcave disc → Calcium oxalate monohydrate
  • Coffin-lid hexagonal → Struvite
  • Flat hexagonal plates → Cystine
  • Rhomboid/needle → Uric acid

• BMP/CMP (creatinine, BUN, electrolytes) — renal function
• Serum calcium — hyperparathyroidism screen
• Serum uric acid
• PTH (if hypercalcemia present)
• Serum phosphate
• CBC — leukocytosis with infected stone

6.2 Imaging

A. Non-contrast CT Abdomen/Pelvis (NCCT) — Gold Standard

As illustrated in the retrieved image: "Axial contrast-enhanced CT scan demonstrating a small, hyperdense focus (white arrow) within the interpolar calyx of the right kidney, characteristic of a renal stone. The CT provides high spatial resolution with distinct corticomedullary differentiation."

• Sensitivity: 95–100%, Specificity: 94–96% (Campbell-Walsh-Wein)
• Detects ALL stone types including radiolucent uric acid stones
• Identifies stone size, location, density (HU), skin-to-stone distance
• Identifies secondary signs: hydronephrosis, perinephric stranding (hydroureter)
• Detects alternative diagnoses (appendicitis, AAA, ovarian pathology)
• HU (Hounsfield Units) of stones:
  • Uric acid: 200–400 HU (lowest)
  • Calcium oxalate: 400–800 HU
  • Calcium phosphate: 800–1200 HU
  • Cystine: ~600 HU
• Low-dose CT protocols now standard to reduce radiation

"MRI fails to clearly identify the stone at the corresponding location... This comparison highlights the superior sensitivity of non-contrast or contrast-enhanced CT over certain MRI sequences for identifying small nephrolithiasis." (Retrieved image caption)

B. Ultrasound (US)

• First-line in children, pregnant women, suspected renal colic without need for immediate intervention
• Sensitivity ~45–67% for ureteral stones (poor mid-ureter visualization)
• Excellent for: hydronephrosis, large renal stones, monitoring
• Can detect twinkling artifact on Doppler — pathognomonic for calculi
• No radiation
• Point-of-care US (POCUS) increasingly used in ED

C. Plain Abdominal X-Ray (KUB — Kidney, Ureter, Bladder)

• Detects radiopaque stones (CaOx, CaPO₄, cystine)
• Radiolucent stones (uric acid, some drug stones) → not visible
• Sensitivity ~44–59%; Specificity ~71–77%
• Useful for monitoring known radiopaque stones
• Useful combined with US (KUB + US) as radiation-sparing alternative to CT

D. CT Urogram (CTU) / IVP (Intravenous Pyelogram)

• IVP largely replaced by CTU
• CTU: Excellent anatomical detail of collecting system; identifies strictures, UPJ obstruction
• Used preoperatively for surgical planning

E. MRI

• Reserved for pregnancy (when US inconclusive) or when CT is contraindicated
• Poor sensitivity for stones (stones appear as signal voids)
• Good for soft tissue evaluation

F. Retrograde Pyelogram (RGP)

• Invasive; reserved for diagnostic uncertainty or during endoscopic procedures
• Gold standard for collecting system anatomy

6.3 Metabolic Evaluation (Stone Prevention Workup)

• First stone in high-risk patients (family history, single kidney, IBD, gout)
• Recurrent stone formers
• Bilateral or multiple stones
• Pediatric stone formers
• AUA Guidelines: recommended for all recurrent stone formers and selected first-time formers

• Serum: Ca, Phosphate, Uric acid, Creatinine, PTH, CO₂, Na, K
• Urinalysis with culture
• Stone analysis (if available)

---

7. MANAGEMENT

7.1 Acute Management of Renal Colic

A. Analgesia (Priority #1)

NSAIDs act by reducing prostaglandin-mediated ureteral smooth muscle tone and decreasing intrarenal pressure — superior analgesic effect in renal colic vs opioids (Campbell-Walsh-Wein).

B. Antiemetics

• Metoclopramide, ondansetron (for nausea/vomiting)

C. IV Fluids

• Correct dehydration
• Forcing fluids is NOT recommended in acute colic — increases collecting system pressure and pain

D. Infection Control

• Infected obstructing stone = UROLOGICAL EMERGENCY
• Urgent decompression (ureteral stent or percutaneous nephrostomy) + IV antibiotics
• Do NOT attempt stone removal in acute infected setting

---

7.2 Medical Expulsive Therapy (MET)

• Tamsulosin 0.4 mg OD — most studied and used (alpha-1a/1d selective)
• Silodosin — highly selective alpha-1a
• Doxazosin, Terazosin — less selective, less commonly used
• Calcium channel blockers (Nifedipine) — some evidence but less than alpha-blockers

• Distal ureteral stone ≤10 mm
• No absolute indication for immediate intervention
• Adequate pain control

1. Failed passage after 4–6 weeks
2. Uncontrolled pain
3. Fever/infection (emergency)
4. Progressive obstruction / deteriorating renal function
5. Solitary kidney with obstruction
6. Bilateral obstructing stones

---

7.3 Surgical Intervention

A. Shock Wave Lithotripsy (SWL)

• Renal stones ≤20 mm (optimal ≤15 mm)
• Proximal ureteral stones ≤10 mm
• Stone composition favorable (CaOx dihydrate, uric acid, struvite)

• Pregnancy (absolute)
• Uncorrected coagulopathy / anticoagulation
• Uncontrolled UTI
• Obstruction distal to stone
• Aortic/renal artery aneurysm near stone
• Morbid obesity, bony deformity (stone cannot be focused)
• Cystine and calcium oxalate monohydrate stones (hard — poor fragmentation)

• Stone-free rate: ~70–85% for renal stones ≤10 mm
• Lower for larger stones, lower pole location, hard stones
• Side effects: hematoma, steinstrasse ("stone street"), hypertension (controversial), renal parenchymal injury

B. Ureteroscopy (URS) + Laser Lithotripsy

• Ureteral stones of any size
• Renal stones ≤20 mm
• SWL failure or contraindication
• Lower pole stones
• Hard stones (cystine, CaOx monohydrate)
• Need for definitive tissue diagnosis
• Pregnancy (can be performed safely)

• Rigid URS — distal/mid ureter
• Semi-rigid URS — up to renal pelvis
• Flexible URS (FURS) / Digital URS — all renal calyces

• Wavelength 2100 nm; absorbed by water
• Fragments all stone types
• Can be used in dusting mode (stone dust <0.5 mm) or fragmentation + basketing mode

• Newer technology; superior fragmentation efficiency, faster dusting
• Lower retropulsion

C. Percutaneous Nephrolithotomy (PCNL)

• Renal stones >20 mm
• Staghorn/struvite stones (partial or complete)
• Lower pole stones >15 mm (where SWL poorly effective)
• SWL/URS failure
• Horseshoe kidney, transplant kidney
• Associated infundibular stenosis requiring simultaneous correction

• Standard PCNL — 24–30 Fr tract
• Mini-PCNL — 14–20 Fr tract
• Ultra-mini PCNL — 11–13 Fr
• Micro-PCNL — 4.8 Fr (for small stones)
• Smaller tracts → less bleeding, faster recovery, but longer operative time

• Stone-free rate: 85–90% for large stones (Campbell-Walsh-Wein)
• Highest stone-free rates of all modalities for complex/large stones

D. Laparoscopic / Robotic-Assisted Surgery

• Pyelolithotomy / Ureterolithotomy
• Indicated for very large stones with concurrent anatomy requiring correction (UPJ obstruction + large stone)
• Largely replaced by PCNL/URS but used in complex cases

E. Open Surgery

• Rare; reserved for failed endourological approaches, complex anatomy, simultaneous reconstruction required

---

7.4 Stone-Type Specific Management

Calcium Stones (Oxalate & Phosphate)

1. Fluid intake — urine output >2.5 L/day (most important)
2. Dietary calcium 1000–1200 mg/day — do NOT restrict (binds intestinal oxalate)
3. Reduce sodium (<2300 mg/day) — reduces calciuria
4. Reduce animal protein (<0.8–1 g/kg/day)
5. Reduce oxalate-rich foods (spinach, nuts, chocolate, tea)
6. Avoid vitamin C megadoses

• Hypercalciuria: Thiazide diuretics (Hydrochlorothiazide 25–50 mg/day, Chlorthalidone) — increase renal tubular calcium reabsorption
• Hypocitraturia: Potassium citrate (30–60 mEq/day) — alkalinizes urine, increases urinary citrate
• Hyperoxaluria (enteric): Calcium carbonate with meals (binds intestinal oxalate), low-fat diet, cholestyramine
• Hyperoxaluria (primary Type 1): Pyridoxine (B6); liver-kidney transplant in severe cases; Lumasiran (siRNA therapy — new)
• Hyperuricosuria contributing to CaOx stones: Allopurinol 300 mg/day, potassium citrate

Uric Acid Stones

1. Oral alkalinization — Potassium citrate 40–80 mEq/day (target urine pH 6.5–7.0)
2. High fluid intake — urine output >2.5 L/day
3. Reduce purine intake (red meat, organ meats, shellfish, beer)
4. Allopurinol 300 mg/day (if hyperuricosuria or hyperuricemia)
5. Febuxostat — alternative xanthine oxidase inhibitor

Struvite (Infection) Stones

• Caused by urease-producing organisms: Proteus mirabilis (most common), Klebsiella, Pseudomonas, Staphylococcus (some strains), Ureaplasma
• Urease splits urea → NH₃ + CO₂ → alkaline urine (pH >7) → struvite precipitation
• Form staghorn calculi (occupying renal pelvis + calyces)
• Cause significant morbidity: recurrent UTI, sepsis, renal damage, end-stage renal disease

1. Complete stone removal is the only cure (bacteria reside within stone matrix)
   • PCNL (procedure of choice for staghorn calculi)
   • SWL (adjunct)
   • Combined approach for complete clearance
2. Perioperative antibiotics based on culture sensitivities
3. Acetohydroxamic acid (AHA) — urease inhibitor; used as adjunct only (poor tolerance, side effects)
4. Urine acidification + antibiotics — maintenance after surgery
5. Long-term surveillance with cultures and imaging

Cystine Stones

• Autosomal recessive disorder of SLC3A1/SLC7A9 gene mutations → defective renal tubular transport of COLA (cystine, ornithine, lysine, arginine) → cystinuria
• Onset in childhood/young adults; highly recurrent
• Cystine solubility only ~250 mg/L

1. Massive hydration — urine output >3–4 L/day (most critical); ≥300 mL/hour overnight
2. Urinary alkalinization — potassium citrate/sodium bicarbonate; target urine pH ≥7.0–7.5
3. Dietary protein restriction — reduce methionine (cystine precursor)
4. Thiol-binding agents (if above insufficient):
   • D-Penicillamine — forms soluble penicillamine-cysteine disulfide; significant side effects
   • Tiopronin (α-Mercaptopropionylglycine, Thiola) — preferred over penicillamine; fewer side effects; forms soluble tiopronin-cysteine complex
   • Captopril — mild effect; third line

• PCNL or URS (cystine is moderately hard; responds to holmium laser)
• Highly recurrent; lifelong monitoring required

---

7.5 Special Populations

Pregnancy

• Incidence ~1 in 200–1500 pregnancies
• 80–85% pass spontaneously
• First-line imaging: Renal ultrasound
• MRI if US inconclusive (no radiation)
• Avoid CT if possible (ionizing radiation)
• Conservative management first (hydration, analgesia — acetaminophen preferred)
• Ureteroscopy with ureteral stenting: safe in all trimesters; preferred over SWL (absolute contraindication in pregnancy)
• Alpha-blockers: not routinely recommended in pregnancy
• PCNL: avoided if possible but can be performed with US guidance

Pediatric Urolithiasis

• Rising incidence (obesity, dietary changes, antibiotic-related dysbiosis)
• Metabolic workup MANDATORY in all children
• Consider primary hyperoxaluria, cystinuria, distal RTA, hypercalcemia
• Genetic testing increasingly important
• Management: SWL (first-line for small stones), ureteroscopy (flexible; smaller instruments), mini-PCNL
• Long-term dietary counseling critical

Single Kidney / Solitary Functional Kidney

• Any obstructing stone = urgent intervention
• Lower threshold for intervention
• Goal: complete stone clearance to prevent recurrence

Renal Transplant

• Stone in transplanted kidney: difficult anatomy (iliac fossa, ureter short)
• URS preferred; PCNL feasible with anterior percutaneous access
• SWL: used cautiously

---

8. STAGHORN CALCULI

• Partial staghorn — 1 calyx + pelvis
• Complete staghorn — pelvis + all major calyceal groups

• PCNL is the standard of care for staghorn calculi
• Complete stone clearance is the goal
• Combined PCNL + SWL ("sandwich therapy") for complex stones
• Anatrophic nephrolithotomy: rarely needed; last resort
• Open surgery: if endourological approach not feasible

---

9. COMPLICATIONS OF UROLITHIASIS

"Stones that form as a result of an upper tract infection, if not appropriately treated, can have devastating consequences and lead to end-stage renal disease." (Harrison's, p. 8691)

---

10. PREVENTION & LONG-TERM FOLLOW-UP

Universal Measures (All Stone Types)

1. Fluid intake: Target urine output >2–2.5 L/day — most evidence-based, most cost-effective intervention
2. Dietary calcium: 1000–1200 mg/day from food (NOT supplements)
3. Reduce sodium (<2300 mg/day)
4. Reduce animal protein — limit to 0.8–1 g/kg/day
5. Normal BMI — weight loss reduces uric acid excretion
6. Lemon juice — citric acid source; increases urinary citrate
7. Stone analysis of all retrieved stones

Stone-Specific Preventive Therapy Summary

Follow-Up Schedule (AUA/EAU Guidelines)

• Stone analysis — all retrieved stones
• 24-hour urine — 6 weeks after starting medical therapy; then every 6–12 months
• Imaging — KUB/US every 6–12 months (CT as needed); avoid excessive CT exposure
• Serum metabolic panel annually
• Compliance assessment with dietary and pharmacological measures

---

11. SUMMARY ALGORITHM

Acute Flank Pain / Suspected Urolithiasis
              ↓
     NCCT Abdomen/Pelvis (Gold Standard)
     [US if pregnant/pediatric]
              ↓
    Stone Confirmed?
    YES → Size, Location, Obstruction?
              ↓
  Fever/Sepsis? → YES → EMERGENCY DECOMPRESSION
  (PCN or DJ stent) + IV Antibiotics
              ↓
        NO INFECTION
              ↓
  Stone ≤10 mm, Distal Ureter, No AKI?
              ↓
  YES → Medical Expulsive Therapy (Alpha-blocker)
        Observe 4–6 weeks
        Adequate analgesia
              ↓
  Passed? → YES → Metabolic workup + Prevention
              ↓
       NO / Larger stone / Failed MET
              ↓
  ┌─────────────────────────────────────────────┐
  │ SURGICAL OPTIONS                            │
  │ • SWL: Renal ≤20mm, Proximal ureter ≤10mm  │
  │ • URS: Ureteral (any size), Renal ≤20mm     │
  │ • PCNL: Renal >20mm, Staghorn, SWL failure  │
  └─────────────────────────────────────────────┘
              ↓
  Stone clearance → Metabolic evaluation
              ↓
  Long-term medical prevention + surveillance

---

QUICK REFERENCE CARD

---